A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder

Trial Profile

A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
  • Indications Alcohol-related disorders; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Alkermes plc
  • Most Recent Events

    • 09 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 17 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Mar 2016 Study design will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top